Previous close | 0.7320 |
Open | 0.7300 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 0.7000 - 0.7500 |
52-week range | 0.7000 - 2.8100 |
Volume | |
Avg. volume | 10,413 |
Market cap | 2.515M |
Beta (5Y monthly) | -0.26 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
GOSSELIES, Belgium, April 10, 2024--Regulatory News: TheraVet (ISIN: BE0974387194 – ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets, reports its 2023 full year and 2024 first quarter revenues.
GOSSELIES, Wallonia, Belgium, March 13, 2024--Regulatory News: TheraVet (ISIN: BE0974387194 – ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets, announces the launch of BIOCERA-VET® Equine in countries already covered by the Company.
GOSSELIE, WALLONIA, Belgium, March 13, 2024--Regulatory News: TheraVet (ISIN: BE0974387194 – ticker: ALVET) (Paris:ALVET), a pioneering company in the management of osteoarticular diseases in pets, announces the launch of BIOCERA-VET® Equine in countries already covered by the Company.